Welcome to our dedicated page for Opgen news (Ticker: OPGN), a resource for investors and traders seeking the latest updates and insights on Opgen stock.
OpGen, Inc. (NASDAQ: OPGN) regularly issues news and regulatory updates that describe its activities in precision medicine, molecular diagnostics, and bioinformatics for infectious disease and antimicrobial resistance. This news page aggregates those disclosures so readers can review how the company presents its business focus, collaborations, financings, and operational changes over time.
Company announcements have covered topics such as research and development collaborations involving antimicrobial resistance panels and genomic surveillance, feature releases for the AREScloud platform, and work related to the Unyvero systems and ARES Technology Platform. OpGen’s releases also discuss financial performance, cash management initiatives, and its own statements about substantial doubt regarding its ability to continue as a going concern, along with potential strategic alternatives it is considering.
Investors and observers can also find information here on equity and financing transactions, including preferred stock financings, warrant inducement agreements, and a securities purchase agreement that allows OpGen to sell common stock to an investor over time. Additional news items describe insolvency proceedings of subsidiaries Curetis GmbH and Ares Genetics GmbH, the sale of their assets by insolvency trustees, and agreements to transfer commercial customer contracts and installed Unyvero systems.
Corporate governance and management changes are another recurring theme in OpGen’s news, including appointments and resignations of directors and executive officers and a 1‑for‑10 reverse stock split intended, according to the company, to support compliance with Nasdaq’s minimum bid price requirement. This page allows readers to follow these developments through the company’s own published statements.
OpGen, Inc. announced preliminary unaudited revenue of approximately $2.7 million for 2022, aligning with its prior guidance. The cash position as of December 31, 2022, stood at $7.4 million. The recent $7.5 million public offering strengthened its balance sheet. Key milestones include a successful UTI clinical trial showing a weighted average sensitivity of 96.4% and specificity of 97.4%, and a collaboration with BioVersys to support a phase II clinical trial. The company has initiated multiple new commercial agreements, enhancing growth prospects for 2023.
OpGen has successfully met several key milestones in collaboration with FIND, triggering milestone payments as of the end of 2022. Key achievements include:
- Demonstration of DNA isolation on the Unyvero A30 cartridge.
- Successful 3-plex assays for pathogen detection and AMR markers.
- Defined product requirements for the target product profile.
OpGen's subsidiary, Curetis, also provided a report on genetic diversity and resistance profiles of pathogens in low and middle-income countries. Looking ahead, the company expects to expand collaboration with FIND, potentially including clinical studies.
OpGen (Nasdaq: OPGN) has successfully closed a public offering of 2,586,207 shares of common stock at $2.90 per share, raising approximately $7.5 million in gross proceeds. The offering includes Series A-1 and Series A-2 warrants with an exercise price of $2.65. The net proceeds will be utilized for various purposes including the commercialization of the Acuitas AMR Gene Panel test, development of the Ares Genetics database, and repayment of certain debts. The offering was conducted under an SEC registration statement effective January 6, 2023.
OpGen, Inc. (Nasdaq: OPGN) has announced a public offering of 2,586,207 shares of common stock at $2.90 per share, with Series A-1 and A-2 warrants also included. The total gross proceeds are expected to be approximately $7.5 million. The funds will support the commercialization of FDA-cleared tests, expand the Ares Genetics database, enhance manufacturing, and pay off outstanding debt. The offering, managed by H.C. Wainwright & Co., is projected to close around January 11, 2023, pending customary conditions.
OpGen, Inc. (Nasdaq: OPGN) announced a 1-for-20 reverse stock split effective January 5, 2023, at 12:01 a.m. EST. This decision, approved by stockholders on November 30, 2022, aims to increase the market price per share to meet Nasdaq's minimum bid requirement of $1.00. The reverse split will reduce outstanding shares from approximately 58 million to about 2.9 million. No fractional shares will be issued, and stockholders entitled to a fractional share will receive cash instead. The change will not affect stockholders' percentage ownership.
OpGen has completed its clinical trial for the Unyvero UTI Panel, enrolling over 1,800 patient samples across four U.S. sites. Preliminary results indicate high performance, with a sensitivity of 96.4% and specificity of 97.4%. The panel is designed to detect a wide range of bacterial and fungal pathogens directly from urine, aiming to improve diagnosis and treatment of urinary tract infections (UTIs). OpGen will use these results to prepare a De Novo request for FDA submission, marking a significant step towards commercialization of this diagnostic tool.
OpGen reported its third quarter 2022 results, highlighting a decline in revenue to approximately $0.4 million from $1.2 million year-over-year. Total revenue for the nine months ended September 30, 2022, was $1.9 million compared to $2.9 million for the same period in 2021. Operating expenses rose significantly to about $14.0 million, leading to a net loss of $14.1 million ($0.30 per share). The company completed two commercial installations of the Acuitas AMR Gene Panel and entered several collaborations, including agreements with BioVersys AG and FIND, while maintaining a cash position of $10.3 million.
OpGen, a precision medicine company, reported preliminary Q3 2022 revenue of approximately $0.4 million, a decline from $1.2 million in Q3 2021. The company's cash position improved to about $13.3 million after a successful financing close. Notable developments included a collaboration agreement with BioVersys, completion of clinical trial enrollment for the Unyvero Urinary Tract Infection Panel, and a registered direct offering grossing $3.38 million. The Nasdaq granted OpGen an extension to meet its bid price requirement, while the company anticipates future impacts from its partnerships.
OpGen, Inc. (NASDAQ: OPGN) will report its third quarter 2022 financial results on November 10, 2022, after U.S. market close. A conference call will follow at 4:30 p.m. EST, where management will discuss the results and business updates. The presentation will be accessible via audio webcast and can be replayed until November 24, 2022. OpGen specializes in molecular diagnostics for infectious diseases and includes products like Unyvero and Acuitas AMR Gene Panel aimed at combating multidrug-resistant organisms.
OpGen has announced a collaboration with BioVersys to deploy its Unyvero platform in a Phase II clinical trial of BV100, an injectable formulation targeting Carbapenem Resistant Acinetobacter baumannii infections. The trial aims to combat high mortality rates associated with ventilator-associated and hospital-acquired pneumonia by improving rapid diagnostics. The Unyvero HPN system will assist in patient enrollment by detecting various pathogens and AMR markers. OpGen's Unyvero platform is positioned as the first market CE IVD marked and FDA cleared sample-to-answer platform for pneumonia diagnostics.